
Supporting cancer biomarker monitoring
Monitoring of treatment efficiency and disease progression using patient-specific genetic biomarkers offers great potential to improve overall survival of cancer patients. Once patient-specific genetic biomarkers have been identified at the clinical site they can be monitored using blood samples or other biopsies.

Enhancing clinical outcomes in cancer care is in our INA®
We are offering as a service the rapid delivery of customised highly sensitive digital and quantitative PCR assays targeting specific and rare mutations for monitoring purposes. Our tumor-informed custom oligo assays are based on our INA® technology allowing for detection of down to a few molecules of single nucleotide variants in liquid biopsies. For Research Use Only.

Custom oligo assays are shipped within just 4 weeks
Our highly experienced reseachers use the provided genetic information to design a customized oligo assay targeting the genetic variation of interest. Our in-house production facilites allow us to manufacture and quality control oligos within a few days and we verify assay performance before dispatch. This enables our customers to initiate monitoring of rare and specific biomarkers soon after they have been identified.

High target specificity is obtained using INA®-based EasyBeacon® probes
By incorporating INA®-based EasyBeacon probes we can design assays with very high target specificity. Assay performance is evaluated using wildtype (WT) and mutated (Mut) templates in melt-based studies as part of the verification process.

Compatible with common digital PCR platforms
Our tumor-informed custom oligo assays for digital PCR are compatible with common digital PCR platforms. The final product is delivered in a dispense ready format including a positive control and a quick guide for easy assay setup.
Our database of previously designed tumor-informed custom oligo assays for digital PCR is constantly expanding. Please inquire about digital PCR assays already made for your target of interest.

